GleamWall
中文EN

AEON AEON Biopharma, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4.09M$14.18M
SG&A expense$12.21M$13.64M
Operating income-$12.80M$72.98M
Pretax income-$39.22M$42.01M
Income tax$0$0
Net income-$39.22M$42.01M
EBITDA-$12.72M$73.08M
EPS (basic)-3.9577.74
EPS (diluted)-3.9572.93
Weighted avg. shares (diluted)9.92M575,945
Balance sheet
Cash & equivalents$3.01M$13,000
Current assets$3.40M$1.59M
PP&E, net$162,000$235,000
Total assets$5.56M$3.14M
Current liabilities$6.90M$14.15M
Total liabilities$60.59M$31.71M
Shareholders' equity-$55.03M-$28.57M
Shares outstanding12.11M555,511
Cash flow statement
Operating cash flow-$17.31M-$20.29M
Capital expenditure$4,000—
Free cash flow-$17.31M—
Investing cash flow-$4,000—
Financing cash flow$20.30M$15.15M
Depreciation & amortization$78,000$97,000
Stock-based compensation$5.32M$6.25M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.